Invitae has made progress in its business realignment plan, cutting cash burn by one-half from 2022 to 2023. However, the company still faces significant challenges. Invitae shares have lost more than ...

Invitae is among the companies pioneering genomics. The company is building a platform that can use DNA to drive smarter healthcare decision-making throughout various life stages. However, the company ...

Invitae is facing two main challenges - assembling a coherent business model from dozens of acquisitions and avoiding a cash crunch looming in 2024/2025. The company has taken decisive action to ...

Invitae Corp. (NVDA) is a leading genomics testing company which was founded in 2010. Its stock price followed the standard Covid-19 boom and bust cycle alongside many peers in 2020 and 2021, which ...

Another biotech company has announced it is coming to the Triangle. Invitae Corp., a medical genetics company based in San Francisco, plans to build a testing and laboratory in Morrisville, according ...